Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.38 |
| ▸ | CA1 | P00915 | 9/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.38 |
| ▸ | CA7 | P43166 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963164 | 0.91 | CA2 (0.40) | CA2CA1CA14CA7CA12 | |
| SCHEMBL291739 | 0.85 | CA1 (0.37) | CA2CA1CA12CA9 | |
| SCHEMBL1780275 | 0.81 | SMN1; SMN2 (0.33) | CA2CA1CA14CA7CA12 | |
| SCHEMBL12583348 | 0.79 | SMN1; SMN2 (0.32) | CA2CA1CA14CA7CA12 | |
| SCHEMBL16508836 | 0.79 | SMN1; SMN2 (0.32) | CA2CA1CA14CA7CA12 | |
| SCHEMBL292581 | 0.77 | TAS1R3 (0.33) | CA2CA12TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL1780277 | 0.77 | TAS1R3 (0.34) | CA2CA1CA12TAS1R3TAS1R1 | |
| SCHEMBL24890636 | 0.76 | CA1 (0.31) | CA2CA1CA12TAS1R3TAS1R1 | |
| SCHEMBL291951 | 0.74 | SMN1; SMN2 (0.48) | CA2CA1CA14CA7CA12 | |
| SCHEMBL19284875 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | CA2 2321/4885CA1 4685/4885CA14 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.